22 results about "Memory disorder" patented technology

The subject of the invention is an application of white birch liquid for improving memory. The invention discloses an application of a betula platyphylla sap extract in preparation of a medicine or a health food, wherein the medicine or the health food is beneficial to improving memory disorder. The invention further discloses a preparation method of the betula platyphylla sap extract, and an application of the betula platyphylla sap extract in preparation of the medicine or the health food. The white birch extract related product disclosed by the invention has the characteristics of high efficiency, safety and convenience, and can be used for effectively treating, preventing or slowing down the dysmnesia in manners of medicines, diet intervention or nutritional health-care products and the like. The invention also provides methods of treating, preventing or slowing memory disorders using the betula platyphylla extract.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The invention provides an electroencephalogram signal-based dysmnesia assessment system, which comprises a signal acquisition module for acquiring an electroencephalogram signal of a target object; the preprocessing module is used for performing 0.5-40Hz band-pass filtering on the electroencephalogram signal of the target object; the signal segmentation module is used for segmenting each channel and determining a plurality of non-overlapping Epoches corresponding to each channel; the feature extraction module is used for performing linear feature extraction and nonlinear feature extraction on each Epoch in each channel, and determining electroencephalogram signal fusion features of the target object based on the linear feature and the nonlinear feature of each Epoch; and the dysmnesia assessment module is used for inputting the electroencephalogram signal fusion features into a trained dysmnesia assessment model, and performing dysmnesia assessment on the target object by using the dysmnesia assessment model to obtain a dysmnesia assessment result of the target object. According to the scheme, dysmnesia evaluation of the target object can be efficiently realized.

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The invention discloses an application of mitochondrial topoisomerase I or a coding gene thereof, relates to the technical field of biological medicines, and particularly provides an application of the mitochondrial topoisomerase I or the coding gene thereof as a therapeutic target in screening or preparing a medicine for treating Alzheimer's disease. The action mechanism of the mitochondrial topoisomerase I in the Alzheimer's disease is fully explored, it is found that deletion of the coding gene of the mitochondrial topoisomerase I can cause increase of APP and A beta levels and finally cause learning and memory impairment similar to the Alzheimer's disease, and the mitochondrial topoisomerase I can be used as a potential target for treatment of the Alzheimer's disease and can be used for treating the Alzheimer's disease. The overexpressed mitochondrial topoisomerase I can significantly reduce APP and A beta levels and treat the Alzheimer's disease.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

The invention discloses a proteolysis targeting chimeric molecule capable of degrading PTBP1 in a targeting manner as well as a preparation method and application of the proteolysis targeting chimeric molecule. The invention relates to a protease targeted chimeric RNA-PTAC of a nucleic acid ligand. The protease targeted chimeric RNA-PTAC is formed by connecting an E3 ubiquitin ligase ligand pomalidomide and an RNA fragment capable of being specifically combined with PTBP1 protein through polyethylene glycol Linker. The invention relates to an RNA-PROTAC (Ribonucleic Acid-PROTAC) brain targeting delivery preparation, which is a complex obtained by coupling cell penetrating peptides TAT and RVG (Recombinant Virus Growth) with the RNA-PROTAC. According to the TR + RNA-PROTAC complex disclosed by the invention, the targets of efficiently degrading PTBP1 protein in vitro and degrading PTBP1 protein in a brain in a targeted manner in vivo are achieved through the complex, and in-vivo experiments also prove that the TR + RNA-PROTAC complex can be used for treating learning and memory disorders of mice caused by A beta and shows a good curative effect of resisting Alzheimer's disease.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The present invention provides a method of treating Parkinson's disease by light stimulation in which light of a specific wavelength such as violet light is irradiated at a specific blinking frequency. The present invention, by irradiating light of a specific wavelength such as violet light to a living body, carries out treatment and / or prophylaxis of Parkinson's disease by improving or suppressing at least one symptom selected from a group of symptoms consisting of cognitive memory disorder, working memory disorder, dysphoria, anxiety, apathy, psychological symptoms (hallucination, visual hallucination, and auditory hallucination), impulse control disorder, orthostatic hypotension, urinary disorder, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorder, pain, weight loss, olfactory abnormality, fatigue, and diaphoresis.

The present invention provides a novel memory disorder ameliorating agent. A PKC [gamma] activity inhibitor is useful as an active ingredient of a dysmnesia ameliorating agent.

The invention discloses an application of HOPX in improving / treating hippocampal dependent dysmnesia. According to the present invention, the rejuvenation or the function up-regulation of the HOPX is directly associated with the aging reversal-related hippocampus memory decline for the first time, and the brand new path and the strategy for treating the age-related cognitive impairment are opened up; in-vivo experiments prove that retrophication / overexpression of HOPX can directly resist hippocampal neurogenesis reduction caused by aging and improve phenotypes from cell and molecule levels. The invention provides a solid theoretical and experimental basis for developing HOPX-based gene therapy, protein drugs or small molecule agonists, and has a good transformation application prospect.

The present invention relates to: a composition for improving cognitive function, comprising a natural extract complex; and use thereof. According to an embodiment of the present invention, a composition for improving cognitive function or memory, comprising one or more selected from the group consisting of a Perilla frutescens var. acuta kudo extract, a Moringa oleifera extract, and a Phyllanthus emblica extract, exhibits few side effects due to being based on natural substances, is readily available, and provides an excellent cognitive function improvement effect while being cost-effective. Therefore, the composition can be effectively used for the prevention, amelioration or treatment of diseases associated with cognitive or memory impairment.

A construction method for an experimental animal learning and memory impairment model, comprising: individually housing a CD-1 mouse to allow the CD-1 mouse to develop territorial awareness; subjecting an experimental mouse and the CD-1 mouse to physical confrontation in a cage for a preset duration; and once the experimental mouse has developed acute violent stress, placing the experimental mouse into a Skinner box apparatus to perform a learning ability test, after a preset duration, performing a memory ability test, and after the tests, obtaining the experimental animal learning and memory impairment model. The method assesses animal learning and memory abilities by means of a Skinner box, expands assessment means related to learning and memory, and provides new data support for the construction and assessment of an animal model involving learning and memory impairment induced by acute violent stress.

This application pertains to a compound of Formula (I), Formula (I'), Formula (I") or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein X, R1, R2, R3, R5, R6, and R7 are as defined herein, and uses of such compounds in methods of treating neurodegenerative diseases, neurodevelopmental disorders, and age-related memory impairment.

The application provides a memory disorder evaluation system based on an electroencephalogram, comprising: a signal acquisition module configured to acquire an electroencephalogram of a target object; a preprocessing module configured to perform a band-pass filtering of 0.5Hz-40Hz on the electroencephalogram of the target object; a signal segmentation module configured to segment each channel and determine a plurality of non-overlapping Epochs corresponding to each channel; a feature extraction module configured to perform linear feature extraction and nonlinear feature extraction on each Epoch in each channel, and determine an electroencephalogram fusion feature of the target object based on the linear feature and the nonlinear feature of each Epoch; and a memory disorder evaluation module configured to input the electroencephalogram fusion feature into a trained memory disorder evaluation model, use the memory disorder evaluation model to evaluate the memory disorder of the target object, and obtain a memory disorder evaluation result of the target object. The scheme can efficiently evaluate the memory disorder of the target object.

The present disclosure relates to a composition for preventing or treating brain-related inflammation disease or neurodegenerative disease, comprising entrectinib. The composition exhibits an effect of inhibiting brain-related inflammation and alleviating memory impairment, and thus may be usefully used for the prevention, alleviation, or treatment of brain-related inflammation disease, neurodegenerative disease, memory impairment, etc.

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

The application belongs to an animal model, and aims to solve the technical problems that the evaluation method of the current Skinner box experimental data lacks a systematic experimental paradigm and evaluation means, and lacks related parameters, and provides an experimental animal learning and memory disorder model, a construction method and application. The traditional chronic social frustration model experiment process is optimized, the learning and memory disorder model of the mouse is stably induced, and the obtained experimental animal learning and memory disorder phenotype is obvious, and the diversity of stress-related disorder animal models is enriched. The learning and memory ability of the animal is evaluated by the Skinner box, the learning and memory related evaluation means is expanded, and new data support is provided for the construction and evaluation of the acute violent stress induced learning and memory disorder animal model.

To provide a method for evaluating dementia, and a composition for preventing or treating a decline in brain function, or for maintaining or improving brain function. [Solution] The gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease were compared. As a result, microorganisms belonging to the genus Faecalibacterium were selected as gut microbiota associated with cognitive function. Furthermore, it was revealed that Faecalibacterium prausnitzii, which possesses specific DNA, has an improving effect on cognitive decline such as learning and memory impairment.

The invention belongs to the technical field of essential oil, and particularly provides compound essential oil for improving learning and memory disorders as well as a preparation method and application of the compound essential oil. The liquid compound essential oil comprises the following raw materials in parts by weight: 30-40 parts of ginseng essential oil, 10-15 parts of rhizoma acori graminei essential oil, 1-5 parts of frankincense essential oil, 30-40 parts of perilla essential oil, 1-5 parts of borneol and 1-5 parts of ginkgo leaf essential oil. The compound essential oil for improving learning and memory disorders provided by the invention takes multiple traditional Chinese medicine extracts as raw materials, so that the compound essential oil has the effects of tonifying qi and inducing resuscitation, refreshing mind and restoring consciousness, soothing nerves and stabilizing mind and enhancing memory.

The invention belongs to the technical field of neurobiology, and particularly relates to a targeted NPTX1-Kv7.2 signal axis for inhibiting neuronal hyperexcitation and improving memory impairment formed by aging. According to the invention, a scene fear memory mouse behavior model is adopted, experimental research is carried out by combining in-vitro brain slice patch clamp recording, single-molecule fluorescence in situ hybridization, immunohistochemistry and other methods, and the result shows that NPTX1 can be used as a cognitive disorder molecular marker, and neuronal hyperactivity caused by aging can be rescued by specifically supplementing NPTX1 in a DG brain region; the activation of DG neurons during scene fear experience is improved, and neuronal activation damage and dysmnesia caused by aging are improved; the retigabine serving as an agonist of the NPTX1 interaction protein Kv7.2 is injected in the intraperitoneal cavity, so that neuron activation damage and dysmnesia caused by senescence can also be effectively improved. The invention discloses the effect of the NPTX1-Kv7.2 signal axis in improving the memory impairment of an aging individual, and provides a new thought and target spot for treating the memory impairment caused by aging.

The present invention relates to a cognitive function and memory improvement composition comprising a natural extract mixture, and a use thereof. The cognitive function or memory improvement composition comprising a Perilla frutescens var. acuta Kudo extract and a peppermint (Mentha piperita) extract, according to one embodiment of the present invention, is based on natural materials and has few side effects, is easily accessible, and has economic efficiency while exhibiting an excellent cognitive function improvement effect, and thus may be usefully employed for the prevention, mitigation, or treatment of cognitive impairment- or memory impairment-related diseases.